Large Study Finds Low Regret After Hormone Therapy Begun in Youth
A new study reports that nearly 97 percent of transgender and gender-diverse people who began hormone therapy as young people say starting treatment was the right decision; only about 3 percent reported regret. The study, published on 9 November 2026 in JAMA Pediatrics, is the largest study yet of satisfaction, regret and perceived harm in this group.
Researchers led by Laura Kuper of the University of Texas Southwestern Medical Center surveyed 376 former patients of one multidisciplinary gender clinic in the US. Participants began estrogen or testosterone as youth — on average at age 16 — and answered surveys between October 2023 and October 2025, an average of 4.9 years after starting treatment, with follow-up ranging from just over a month to 10.7 years. Regret was measured with the Decision Regret Scale, scored from 0 to 100.
Of the 372 who completed the scale, 360 (96.8 percent) said hormone therapy was the right decision, 10 (2.7 percent) reported regret, and 7 (1.9 percent) said they felt harmed; all seven who reported harm also reported regret. The average regret score was 4.3 out of 100, median zero — well below the 16.5 average in a meta-analysis of decision regret across many medical treatments. Most, 311 of 376 (82.7 percent), were still taking hormones when surveyed; 65 (17.3 percent) had stopped.
Regret scores were higher among those who had stopped hormones and those who identify on the nonbinary spectrum, though they remained low in absolute terms in both groups. Neither regret nor harm was linked to age at treatment start or to gender diversity shown before puberty. In written answers, the nine who described regret or harm pointed to physical changes they no longer wanted, side effects, or feeling unprepared to make an informed decision.
The authors list several limits. All participants came from one clinic, and the sample was 93.6 percent White. About 40 percent of those invited did not respond, so the views of non-respondents are unknown. It relied on self-reports, did not record why participants stopped treatment, and measured satisfaction with the decision, not with specific physical effects. Channa Jayasena, a reproductive endocrinology consultant at Imperial College London, told the Science Media Centre the study was "well-conducted and large" but noted the non-response and the lack of record-linked outcomes or a comparison group.
The findings fit earlier research, which has put regret after youth gender-affirming care at roughly 0.3 to 4 percent. Scott Leibowitz, a child and adolescent psychiatrist on the board of the World Professional Association for Transgender Health, said it "adds to the growing evidence base that demonstrates individualized gender-affirming care can be beneficial for a young person." The authors conclude the results support existing standards of care and "do not support efforts to categorically restrict or ban access" to hormone therapy for young people. That lands as 28 US states limit youth access, according to KFF, and after the Supreme Court upheld Tennessee's ban in June 2025.



